Next-Generation Bio-Sensing Platform for

Gemina Labs has developed and patented a transformative bio-chemistry that powers next-generation testing platforms for detecting a wide range of pathogens that affect humans and animals. Our tests are fast, affordable and accurate, and easily self-administered providing consumers with direct solutions where they need them.

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Company Highlights

Market
With speed, affordability, and accuracy at the center of Gemina’s technology, the market opportunities in diagnostics range from applications like in-vitro diagnostics for human health ($83 BN) to the contract cleaning services market ($292 BN).
Team
Gemina’s team is comprised of industry-leading experts in the research, development, and commercialization of biotechnologies.
Innovative Technology
Watch how Gemina’s next-gen biosensing unlocks entry in multiple markets via an innovative platform for pathogen detection that is a simple, affordable, effective, and non-invasive antigen test that returns results in minutes, coupled with a digital risk management system.
Intellectual Property
Gemina is a world-leading developer of novel surface binders, which are the key to enabling the speed, affordability, and accuracy of our platform for pathogen detection.
Democratizing Diagnosis
The keys to democratize access to diagnosis are speed, affordability, and accuracy. Gemina’s next-generation platform unlocks the opportunity.
Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

What the Experts Say

"The Gemina Labs dual affinity probe technology establishes a flexible and novel approach to attaching functional biomolecules to diverse surfaces …The technology has been evaluated by Paragreen and offers significant potential competitive advantages including increased performance and cost efficiency in applications ranging from human and veterinary diagnostics to environmental testing, food safety, agriculture, and industrial bioprocessing.”
Prof. Mike Catt, Paragreen Associates, and inventor for the Clearblue® pregnancy test
Stay Informed

The Testing Platform Powering the Future

Traditional

  • Single function
  • Qualitative result (ie. Yes/No)

The Future with Gemina

We're building a new category of biosensors - moving diagnosis out of the clinic and into the hands of the patient and user...

Multi-Function Tests

We are creating a future where taking one test will tell you more than whether you are infected or not. What if one test could tell you whether you have Influenza...or Covid, or neither? Powered by Gemina's chemistry, we are developing affordable, disposable "Multiplexed" testing devices.

Quantitative Results

We are building a future where tests are more than "+ve" or "-ve" results. Gemina devices will deliver values that enable the daily monitoring of wellbeing and chronic conditions.

Digital Integration

Results can go straight to Testpoint, Gemina's digital smartphone application, and integrate into other data systems (healthcare providers, employer, etc.)

BEYOND HUMAN HEALTH

Gemina's product development roadmap goes beyond direct human health and wellbeing applications. Our technology will be used in sectors by proactively testing to protect human health.

A Deep Bench of Expertise

Gemina’s team is comprised of industry-leading experts in the research, development, and commercialization of biotechnologies.

Team

Brian Firth,
CEO

  • 35 years focused on point-of-care diagnostics

  • 8 years at Swiss Precision Diagnostics, the owner of Clearblue as Managing Director of SPD’s UK subsidiary before becoming Chief Operating Officer

Rob Greene,
CTO

  • Founder Eco Mine Technologies

  • M.Eng, UBC in surface chemistry

James Tansey,
Director

  • Assoc. Prof Sauder School of Business

  • Founder of NatureBank Asset Management

  • Deputy Director James Martin Institute, Oxford

Martin Cronin,
Director

  • 20 years of experience with the British Government. Extensive national and international relationships. Served as CEO and director of companies including threat detection specialist, Patriot One (TSX: PAT)

Mike Liggett,
CFO

  • 7 years with PWC

  • B.Sc in pharmaceutical sciences

David Browning, HEAD OF PRODUCTIZATION

  • 40 years in life science product innovation, including: Amersham, J&J (Ortho Clinical Diagnostics) IGEN (Roche lead IVD platform) Philips Healthcare

Dr. Christine Buerki,
Head of Chemistry

  • PhD in molecular biology & immunology(University of Zurich)

  • 14 years in biotechnology companies

Elliot Hong,
VP DEVELOPMENT

  • A senior engineering lead and product development executive, with a career spent in the medical device space

Mike Kennedy,
HEAD OF DIGITAL

  • PhD in management information systems(U Washington)

  • Research fellow in sustainable data systems, UBC

John Davies,
CHAIRMAN OF THE BOARD

  • Syniad Innovations CEO

  • Scientific Research Capital CEO

  • IP Group CFO, COO

  • IndexIT Partnership CFO

Advisory Board

Dr. Mike Catt

Professor and Turing Fellow, Newcastle University. Career in vitro diagnostic product development (Swiss Precision, Unilever) including pioneering the development of the Clearblue lateral flow assay pregnancy test. At Unilever he led the Healthy Aging program for integrated technologies for lifestyle interventions.

Hugh MacNaught

Executive with thirty years experience in Fortune 100 companies in the development of life science technologies. Worked in product development with Amersham, Kodak Diagnostics, Boehringer Mannheim and others. Background includes extensive experience in clinical diagnostics, therapeutics and diagnostic imaging.

Rob Porter

CEO and founder of RAPivD, a scientific R&D company focused on diagnostics platforms such as lateral flow, electrochemical and op to electrical systems. He began his career with Unilever before transferring to the UK’s NationalPhysics Laboratory, building a bio sensing patent portfolio before spinning out Argento Diagnostics.Subsequently, Rob has held seniorBoard positions (CEO, CTO, COO) with a slate of UK diagnostic companies and has recently served as an adviser to the UK Health Service in respect of scale-up manufacturing for COVID rapid testing.

Andrew Rae

Early career as a biotech analyst, launched career as an executive and board positions in biotechnology companies in Canada and the US. Responsible for commercial transactions with Alexion Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, and JDR.

Press and Updates

Gemina Labs Appoints Diagnostic Executive Brian Firth as Chief Executive Officer

September 6, 2022
Read More

GEMINA LABS ANNOUNCES CE MARK FOR ITS FIRST PRODUCT – THE BEST IN CLASS LEGIO-XTM COVID RAPID ANTIGEN TEST

May 17, 2022
Read More

GEMINA LABS COMPLETES SUCCESSFUL HUMAN CLINICAL PERFORMANCE EVALUATION ON ITS LEGIO XTM COVID-19 RAPID ANTIGEN TEST

May 5, 2022
Read More

GEMINA LABS STRATEGIC UPDATE: FROM PRODUCT TO PLATFORM, GEMINA PROVIDES A TECHNOLOGY ROADMAP

February 15, 2022
Read More
Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.
Become an Investor
Download Investor Deck

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Download Company Deck

Thank you. Your submission has been received.
Oops! Something went wrong while submitting the form.